Erratum: Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia (Prostate Cancer and Prostatic Diseases (2013) 16 (292-300) DOI: 10.1038/pcan.2013.21);Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 4, 2013, Pages 292-300

  Devaney, J M ^a   Wang, S ^b,c   Funda, S ^a   Long, J ^b   Taghipour, D J ^b   Tbaishat, R ^c   Furbert Harris, P ^b,c   Ittmann, M ^d   Kwabi Addo, B ^b,c  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b HOWARD UNIVERSITY CANCER CENTER   (United States)

^c HOWARD UNIVERSITY   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Gene expression; Genome wide DNA methylation analysis; Pyrosequencing

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ARTICLE; BNC1 GENE; CANCER GRADING; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; CXXC5 GENE; CYB5R2 GENE; DNA METHYLATION; EPIGENETICS; FOS GENE; FZD1 GENE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE INACTIVATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IFN GAMMA GENE; IL 1 GENE; IL 6 GENE; LMX1B GENE; MALE; ONCOGENE MYC; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RPL39L GENE; SYN2 GENE; TNF GENE; TUMOR SUPPRESSOR GENE; ZNF783 GENE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL LINE, TUMOR; CLUSTER ANALYSIS; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM GRADING; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, DNA;

EID: 84887609207     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.58     Document Type: Erratum

References (54)

1. Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 2006; 66: 10242-10246.
2. Macaluso M, Paggi MG, Giordano A. Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. Oncogene 2003; 22: 6472-6478.
3. NelsonWG, Yegnasubramanian S, Agoston AT, Bastian PJ, Lee BH, Nakayama M et al. Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci 2007; 12: 4254-4266.
4. Kwabi-Addo B, Chung W, Shen L, Ittmann M, Wheeler T, Jelinek J et al. Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res 2007; 13: 3796-3802.
5. Hmadcha A, Bedoya FJ, Sobrino F, Pintado E. Methylation-dependent gene silencing induced by interleukin 1beta via nitric oxide production. J Exp Med 1999; 190: 1595-1604.
6. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-2054.
7. Perry AS, Foley R, Woodson K, Lawler M. The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr Relat Cancer 2006; 13: 357-377.
8. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6-21.
9. Illingworth RS, Bird AP. CpG islands-'a rough guide'. FEBS Lett 2009; 583: 1713-1720.
10. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692.
11. Ongenaert M, Van NL, De MT, Menschaert G, Bekaert S, Van Criekinge W. PubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic Acids Res 2008; 36: D842-D846.
12. Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005; 97: 103-115.
13. Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H, Sunderji A et al. Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One 2009; 4: e4830.
14. Laird PW. Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet 2010; 11: 191-203.
15. Yegnasubramanian S, Nelson WG. Genome-wide DNA methylation analysis in cancer research. In: Yegnasubramanian S, Isaac WB (eds). Modern Biology: Approaches for Unbiased Discovery in Cancer Research. Springer: New York, NY, USA, 2010, pp 47-66.
16. Sandoval J, Heyn H, Moran S, Serra-Musach J, Pujana MA, Bibikova M et al. Validation of a DNA methylation microarray for 450 000 CpG sites in the human genome. Epigenetics 2011; 6: 692-702.
17. Liu Y, Aryee MJ, Padyukov L, Fallin MD, Hesselberg E, Runarsson A et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol 2013; 31: 142-147.
18. Sapienza C, Lee J, Powell J, Erinle O, Yafai F, Reichert J et al. DNA methylation profiling identifies epigenetic differences between diabetes patients with ESRD and diabetes patients without nephropathy. Epigenetics 2011; 6: 20-28.
19. Toperoff G, Aran D, Kark JD, Rosenberg M, Dubnikov T, Nissan B et al. Genome-wide survey reveals predisposing diabetes type 2-related DNA methylation variations in human peripheral blood. Hum Mol Genet 2012; 21: 371-383.
20. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987; 196: 261-282.
21. Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou L et al. Comparison of betavalue and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 2010; 11: 587.
22. Polnaszek N, Kwabi-Addo B, Peterson LE, Ozen M, Greenberg NM, Ortega S et al. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res 2003; 63: 5754-5760.
23. Kwabi-Addo B, Wang J, Erdem H, Vaid A, Castro P, Ayala G et al. The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res 2004; 64: 4728-4735.
24. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ et al. A networkbased analysis of systemic inflammation in humans. Nature 2005; 437: 1032-1037.
25. Kim SJ, Kelly WK, Fu A, Haines K, Hoffmann A, Zheng T et al. Genome-wide methylation analysis identifies involvement of TNF-alpha mediated cancer pathways in prostate cancer. Cancer Lett 2011; 302: 47-53.
26. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003; 33: 245-254.
27. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428.
28. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301: 89-92.
29. Ahmed H. Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples. Biomark Cancer 2010; 2010: 17-33.
30. Kwabi-Addo B, Wang S, Chung W, Jelinek J, Patierno SR, Wang DB et al. Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res 2010; 16: 3539-3547.
31. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980; 20: 85-93.
32. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19: 187-191.
33. Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, Erdjument-Bromage H et al. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet 1999; 23: 58-61.
34. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103-107.
35. Tseng H, Biegel JA, Brown RS. Basonuclin is associated with the ribosomal RNA genes on human keratinocyte mitotic chromosomes. J Cell Sci 1999; 112(Pt 18): 3039-3047.
36. Boldrup L, Coates PJ, Laurell G, Nylander K. p63 Transcriptionally regulates BNC1, a Pol I and Pol II transcription factor that regulates ribosomal biogenesis and epithelial differentiation. Eur J Cancer 2012; 48: 1401-1406.
37. Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clark N, Brown M et al. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 2010; 29: 2104-2117.
38. Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z et al. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics 2010; 5: 499-508.
39. Wu QL, Zierold C, Ranheim EA. Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia. Blood 2009; 113: 3031-3039.
40. Salpea P, Russanova VR, Hirai TH, Sourlingas TG, Sekeri-Pataryas KE, Romero R et al. Postnatal development-and age-related changes in DNA-methylation patterns in the human genome. Nucleic Acids Res 2012; 40: 6477-6494.
41. Holcombe RF, Marsh JL, Waterman ML, Lin F, Milovanovic T, Truong T. Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol Pathol 2002; 55: 220-226.
42. Zhang H, Zhang X, Wu X, Li W, Su P, Cheng H et al. Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/betacatenin pathway. Cancer Lett 2012; 323: 106-113.
43. Flahaut M, Meier R, Coulon A, Nardou KA, Niggli FK, Martinet D et al. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. Oncogene 2009; 28: 2245-2256.
44. Ball MP, Li JB, Gao Y, Lee JH, Leproust EM, Park IH et al. Targeted and genomescale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 2009; 27: 361-368.
45. Brenet F, Moh M, Funk P, Feierstein E, Viale AJ, Socci ND et al. DNA methylation of the first exon is tightly linked to transcriptional silencing. PLoS One 2011; 6: e14524.
46. Perry AS, O'Hurley G, Raheem OA, Brennan K, Wong S, O'Grady A et al. Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer. Int J Cancer 2012; 132: 1771-1780.
47. Wang S, Dorsey TH, Terunuma A, Kittles RA, Ambs S, Kwabi-Addo B. Relationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancer. PLoS One 2012; 7: e37928.
48. Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treat Rev 2009; 35: 18-31.
49. Deeken JF, Cormier T, Price DK, Sisung TM, Steinberg SM, Tran K et al. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J 2010; 10: 191-199.
50. Jeronimo C, Varzim G, Henrique R, Oliveira J, Bento MJ, Silva C et al. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2002; 11: 445-450.
51. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz ZA, Nelson WG et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol 2003; 163: 923-933.
52. Yamanaka M, Watanabe M, Yamada Y, Takagi A, Murata T, Takahashi H et al. Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer 2003; 106: 382-387.
53. Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004; 10: 8472-8478.
54. Jeronimo C, Henrique R, Hoque MO, Ribeiro FR, Oliveira J, Fonseca D et al. Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res 2004; 10: 4010-4014.